Trial ID or NCT#





This pilot clinical study, funded by the National Institutes of Health, will evaluate the safety and metabolic responses to a licensed inactivated seasonal influenza vaccine (TIV). This single arm study will consist of two cohorts: MELAS syndrome volunteers (a specific identified disorder of mitochondrial dysfunction: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) between 13-60 years for OR adult control volunteers between 18-65 years of age. Both cohorts will receive the same treatment: a single vaccination with an FDA-licensed intramuscular seasonal trivalent inactivated influenza vaccine (TIV).

Official Title

Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease

Eligibility Criteria

Ages Eligible for Study: 13 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes


Gregory Enns
Professor of Pediatrics (Genetics) at the Lucile Salter Packard Children's Hospital
Cornelia L. Dekker, M.D.
Professor (Research) of Pediatrics (Infectious Diseases), Emerita

Contact us to find out if this trial is right for you.


Greg Enns, MD
(650) 498-5798